Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$20.21 USD
+0.84 (4.34%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $20.39 +0.18 (0.89%) 6:08 PM ET
2-Buy of 5 2
A Value B Growth B Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PCRX 20.21 +0.84(4.34%)
Will PCRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PCRX
Should Value Investors Buy Pacira BioSciences (PCRX) Stock?
Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
PCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Pacira (PCRX) Up 1.7% Since Last Earnings Report?
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues
Here's What Key Metrics Tell Us About Pacira (PCRX) Q1 Earnings
Other News for PCRX
ClearBridge Small Cap Growth Strategy Q2 2024 Commentary
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
Insider Sale: Chief Medical Officer Jonathan Slonin Sells Shares of Pacira BioSciences Inc (PCRX)
Insider Sale: Chief Administrative Officer Kristen Williams Sells Shares of Pacira BioSciences ...
Insider Sale at Pacira BioSciences Inc (PCRX): Senior Vice President, Finance Lauren Riker ...